Literature DB >> 25470395

Towards a "metabolic" subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction.

Celina S Liu, Andre F Carvalho, Roger S McIntyre1.   

Abstract

Major depressive disorder (MDD) is frequently associated with significant cognitive dysfunction. Furthermore, MDD is often co-morbid with obesity and metabolic disorders. The aim of this review is to evaluate the pathophysiological role obesity and co-morbid metabolic disorders may play in cognitive dysfunction associated with MDD. We conducted a PubMed search from December 1(st) 2013 to May 31(st) 2014 of all English language publications including the following keywords: cognition, working memory, attention, executive functioning, inflammation, insulin, brain-derived neurotrophic factor, neurotrophins, incretins, glucagon-like peptide-1, adipokines, diabetes, oxidative stress and glucocorticoids, cross- referenced with MDD and obesity, metabolic disorders, or metabolic syndrome. Clinical and epidemiological studies indicate that metabolic disturbances may contribute to cognitive dysfunction in MDD. There are several overlapping pathophysiological mechanisms linking obesity and metabolic abnormalities to MDD including disturbances in the hypothalamic pituitary adrenal axis, abnormalities in brain-derived neurotrophic factor signaling, adipose-derived hormones, insulin signalling, inflammatory cytokines, as well as oxidative and nitrosative stress pathways. Based on current research results, this article presents several putative mechanisms underlying the effects of obesity and metabolic abnormalities on cognitive dysfunction in MDD. Metabolic MDD may represent a depression subtype with unique patho-etiological mechanisms. The diverse shared pathophysiological mechanisms elucidated in this review may provide novel targets for the prevention and/or treatment of cognitive deficits in MDD.

Entities:  

Mesh:

Year:  2014        PMID: 25470395     DOI: 10.2174/1871527313666141130204031

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  12 in total

1.  Depression and risk of type 2 diabetes: the potential role of metabolic factors.

Authors:  N Schmitz; S S Deschênes; R J Burns; K J Smith; A Lesage; I Strychar; R Rabasa-Lhoret; C Freitas; E Graham; P Awadalla; J L Wang
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

Review 2.  The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.

Authors:  Roger S McIntyre; Holly X Xiao; Kahlood Syeda; Maj Vinberg; Andre F Carvalho; Rodrigo B Mansur; Nadia Maruschak; Danielle S Cha
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

3.  Brain and behavioral correlates of insulin resistance in youth with depression and obesity.

Authors:  Manpreet K Singh; Sara M Leslie; Mary Melissa Packer; Yevgeniya V Zaiko; Owen R Phillips; Elizabeth F Weisman; Danielle M Wall; Booil Jo; Natalie Rasgon
Journal:  Horm Behav       Date:  2018-04-23       Impact factor: 3.587

Review 4.  An Overview of Links Between Obesity and Mental Health.

Authors:  Christian Avila; Alison C Holloway; Margaret K Hahn; Katherine M Morrison; Maria Restivo; Rebecca Anglin; Valerie H Taylor
Journal:  Curr Obes Rep       Date:  2015-09

5.  Bifidobacterium pseudocatenulatum CECT 7765 Ameliorates Neuroendocrine Alterations Associated with an Exaggerated Stress Response and Anhedonia in Obese Mice.

Authors:  Ana Agusti; A Moya-Pérez; I Campillo; S Montserrat-de la Paz; V Cerrudo; A Perez-Villalba; Yolanda Sanz
Journal:  Mol Neurobiol       Date:  2017-09-18       Impact factor: 5.590

6.  The Association of Free Fatty Acids and Eicosanoids with the Severity of Depressive Symptoms in Stroke Patients.

Authors:  Dariusz Kotlega; Agnieszka Zembron-Lacny; Monika Golab-Janowska; Przemyslaw Nowacki; Malgorzata Szczuko
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

7.  Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.

Authors:  Marlene P Freeman; Rebecca S Hock; George I Papakostas; Heidi Judge; Cristina Cusin; Sanjay J Mathew; Gerard Sanacora; Dan V Iosifescu; Charles DeBattista; Madhukar H Trivedi; Maurizio Fava
Journal:  J Clin Psychopharmacol       Date:  2020 May/Jun       Impact factor: 3.118

Review 8.  Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review.

Authors:  Young Sup Woo; Hye-Jin Seo; Roger S McIntyre; Won-Myong Bahk
Journal:  Int J Mol Sci       Date:  2016-01-12       Impact factor: 5.923

9.  Depression Amplifies the Influence of Central Obesity on 10-Year Incidence of Diabetes: Findings from MIDUS.

Authors:  Vera K Tsenkova; Arun Karlamangla
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

10.  Identification of three genetic variants as novel susceptibility loci for body mass index in a Japanese population.

Authors:  Yoshiki Yasukochi; Jun Sakuma; Ichiro Takeuchi; Kimihiko Kato; Mitsutoshi Oguri; Tetsuo Fujimaki; Hideki Horibe; Yoshiji Yamada
Journal:  Physiol Genomics       Date:  2018-01-12       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.